Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

EDITORIAL

Criteria for deciding cost-effectiveness for expensive new anti-cancer agents

Sarin Rajiv

Year : 2008| Volume: 4| Issue : 1 | Page no: 1-2

   This article has been cited by
 
1 Deficiencies of Methods Applied in Cost Effectiveness Analysis of Hematological Malignancies
Nicolas Batty,Joseph Shatzel,Samuel Wiles,Mathew Kabalan,Rohit Sharma,Jonathan Pang,David Yi,Iris Alatovic,Sana Saif,Deepika Narasimha,Joseph LaPenna,Anthony Troitino,Kristopher Attwood,Michael Weinstein,Eric Murawski,Mathew Valerio,Yong Yin,Meir Wetzler
Journal of Cancer Policy. 2014;
[Pubmed]  [Google Scholar] [DOI]
2 Assessing the need for quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies
Bosetti, R. and Marneffe, W. and Vereeck, L.
Nanomedicine. 2013; 8(3): 487-497
[Pubmed]  [Google Scholar]
3 A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
Lopes, G. and Glück, S. and Avancha, K. and Montero, A.J.
Breast Cancer Research and Treatment. 2013; 137(1): 187-193
[Pubmed]  [Google Scholar]
4 Health economics and cost-effectiveness research with special reference to hemato-oncology
Rajat Kumar
Medical Journal Armed Forces India. 2013; 69(3): 273
[Pubmed]  [Google Scholar] [DOI]
5 A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
Gilberto Lopes,Stefan Glück,Kiran Avancha,Alberto J. Montero
Breast Cancer Research and Treatment. 2013; 137(1): 187
[Pubmed]  [Google Scholar] [DOI]
6 Assessing the need for quality-adjusted cost–effectiveness studies of nanotechnological cancer therapies
Rita Bosetti,Wim Marneffe,Lode Vereeck
Nanomedicine. 2013; 8(3): 487
[Pubmed]  [Google Scholar] [DOI]
7 Robot-assisted Radical Prostatectomy – Fake Innovation or the Real Deal?
Peter C. Albertsen
European Urology. 2012; 62(3): 365
[Pubmed]  [Google Scholar] [DOI]
8 The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs
George Dranitsaris,Ilse Truter,Martie S. Lubbe,Wayne Cottrell,Biljana Spirovski,Jonathan Edwards
Journal of Evaluation in Clinical Practice. 2012; 18(2): 343
[Pubmed]  [Google Scholar] [DOI]
9 The economic pressures for biosimilar drug use in cancer medicine
Paul Cornes
Targeted Oncology. 2012; 7(S1): 57
[Pubmed]  [Google Scholar] [DOI]
10 Robot-assisted radical prostatectomy - Fake innovation or the real deal?
Albertsen, P.C.
European Urology. 2012; 62(3): 365-367
[Pubmed]  [Google Scholar]
11 The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs
Dranitsaris, G. and Truter, I. and Lubbe, M.S. and Cottrell, W. and Spirovski, B. and Edwards, J.
Journal of Evaluation in Clinical Practice. 2012; 18(2): 343-351
[Pubmed]  [Google Scholar]
12 A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe
Dranitsaris, G. and Ortega, A. and Lubbe, M.S. and Truter, I.
Journal of Oncology Pharmacy Practice. 2012; 18(1): 57-67
[Pubmed]  [Google Scholar]
13 Global disparities in cancer care: The ABCD for access and the inverse care law
Sarin, R.
Journal of Cancer Research and Therapeutics. 2011; 7(3): 249-250
[Pubmed]  [Google Scholar]
14 Advances in cancer therapeutics and patient access to new drugs
Dranitsaris, G. and Truter, I. and Lubbe, M.S. and Amir, E. and Evans, W.
PharmacoEconomics. 2011; 29(3): 213-224
[Pubmed]  [Google Scholar]
15 Delivering affordable cancer care in high-income countries
The Lancet Oncology. 2011; 12(10): 933
[HTML Full text]  [Google Scholar] [DOI]
16 The economic pressures for biosimilar drug use in cancer medicine
P. Cornes
ONCOLOGIE. 2011;
[HTML Full text]  [Google Scholar] [DOI]
17 Advances in Cancer Therapeutics and Patient Access to New Drugs
George Dranitsaris,Ilse Truter,Martie S. Lubbe,Eitan Amir,William Evans
PharmacoEconomics. 2011; 29(3): 213
[Pubmed]  [Google Scholar] [DOI]
18 Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Nitin N. Sriramanakoppa, Vivian M. Mendonca, Sangameshwar B. Mahagaonkar
International Journal of Technology Assessment in Health Care. 2011; 27(1): 23
[HTML Full text]  [Google Scholar] [DOI]
19 Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing
Hillner, B.E., Smith, T.J.
Journal of Clinical Oncology. 2009; 27(13): 2111-2113
[Pubmed]  [Google Scholar]
20 Particle therapy in clinical practice: Is there enough evidence to justify the current surge in interest?
Jalali, R.
Journal of Cancer Research and Therapeutics. 2008; 4(2): 54-56
[Pubmed]  [Google Scholar]

 

Read this article